Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients

Melanoma Research

Volumn 16, Issue 5, 2006, Pages 405-411

  Tas, Faruk ^a   Duranyildiz, Derya ^a   Oguz, Hilal ^a   Camlica, Hakan ^a   Yasasever, Vildan ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Angiogenesis; Angiogenin; Melanoma; Transforming growth factor 1; Vascular endothelial growth factor; Vascular endothelial growth factor receptor 1; Vascular endothelial growth factor receptor 2

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER STAGING; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SKIN TUMOR; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INDUCING AGENTS; CELL PROLIFERATION; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; RIBONUCLEASE, PANCREATIC; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33749433061     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000222598.27438.82     Document Type: Article

References (25)

1. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19:1207-1225.
2. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-1027.
3. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997; 76:930-934.
4. Claffey KPM, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseav EJ, et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56:172-181.
5. Simonetti O, Lucarini G, Brancorsini D, Nita P, Bernardini ML, Biagini G, et al. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 2002; 95:1963-1970.
6. Viac J, Schmitt D, Claudy A. Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma. Cancer Lett 1998; 125:35-38.
7. Redondo P, Bandres E, Solano T, Okroujnov I, Garcia-Foncillas J. Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro. Cytokine 2000; 12:374-378.
8. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19:577-583.
9. Redondo P, Sanchez-Carpintero I, Bauza A, Idoate M, Solano T, Mihm MC Jr. Immunologic escape and angiogenesis in human malignant melanoma. J Am Acad Dermatol 2003; 49:255-263.
10. Pelletier F, Bermont L, Puzenat E, Blanc D, Cairey-Remonnay S, Mougin C. Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Br J Dermatol 2005; 152:685-689.
11. Straume O, Akslen LA. Expression of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001; 159:223-235.
12. Stefanou D, Batistatou A, Zioga A, Arkoumani E, Papachristou D, Agnantis N. Immunohistochemical expression of vascular endothelial growth factor and C-KIT in cutaneous melanocytic lesions. Int J Surg Pathol 2004; 12:133-138.
13. Pisacane AM, Risio M. VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas. Melanoma Res 2005; 15:39-43.
14. Shimoyama S, Yamasaki K, Kawahara M, Kaminishi M. Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin Cancer Res 1999; 5:1125-1130.
15. Li D, Bell J, Brown A, Berry CL. The observation of angiogenin and basic fibroblast growth factor gene expression in human colonic adenocarcinomas, gastric carcinomas, and hepatocellular carcinomas. J Pathol 1994; 172:171-175.
16. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer 1999; 86:316-324.
17. Hartmann A, Kunz M, Kostlin S, Gillitzer R, Toksoy A, Brocker EB, et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 1999; 59:1578-1583.
18. Kaminska B,Wesolowska A, Danilkiewicz M. TGF beta signalling and its role in tumor pathogenesis. Acta Biochim Pol 2005; 52:329-337.
19. Hussein MR. Transforming growth factor-α and malignant melanoma: molecular mechanisms. J Cutan Pathol 2005; 32:389-395.
20. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005; 23:2078-2093.
21. Schmid P, Itin P, Rufli T. In situ analysis transforming growth factor-betas (TGF-beta1, TGF-beta2, TGF-beta3), and TGF-beta type II receptor expression in malignant melanoma. Carcinogenesis 1995; 16:1499-1503.
22. Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, et al. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 1997; 7:313-321.
23. Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 1998; 77:1492-1494.
24. Balch CM, Buzaid AC, Soong S-J, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
25. Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour developmentin cutaneous malignant melanoma. Genes Immun 2002; 3:229-232.